Weight loss intervention for underserved communities in Louisiana

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of a multi-level obesity intervention called LA-CEAL CONNECT in promoting weight loss among low-income and underserved adults living with obesity in Louisiana. The study will compare this intervention to enhanced usual care to determine its impact on weight loss, waist circumference, diet quality, physical activity, quality of life, and blood pressure over 6 and 12 months. Additionally, it will assess the feasibility and sustainability of implementing the intervention in these communities. Participants will receive health coaching, culturally tailored materials, and remote monitoring to support their weight loss journey.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* being 18 to 75 years of age
* living with obesity, defined as a BMI between 30 and 50 kg/m2 for non-Asian identifying participants and BMI between 27.5 and 50 kg/m2 for Asian-identifying participants
* weighing less than 400 pounds
* receiving care from or willing to register at a participating FQHC clinic
* able to understand and speak English
* able to complete the study within the next year (e.g., not planning to move from the area within study period)

Exclusion Criteria:

* having given birth within the past year, pregnant or planning to become pregnant during study period (within 1 year)
* currently participating in a weight-loss program
* having lost more than 10 pounds in the last 6 months
* being an employee or a family member of an employee of any participating FQHC
* having a disease that can interfere with or be aggravated by exercise or weight loss

Where it's running

• InclusivCare - Avondale Clinic
  Avondale, Louisiana, United States Recruiting
• CommuniHealth Services - Bastrop Clinic
  Bastrop, Louisiana, United States Recruiting
• CareSouth Medical and Dental - Baton Rouge Clinic
  Baton Rouge, Louisiana, United States Recruiting
• Teche Action Clinic - Franklin
  Franklin, Louisiana, United States Recruiting
• Southeast Community Health Systems - Greensburg Clinic
  Greensburg, Louisiana, United States Recruiting
• Teche Action Clinic - Houma
  Houma, Louisiana, United States Recruiting

Study contacts

• Principal investigator: Marie Krousel-Wood, MD, MSPH — Tulane University
• Study coordinator: Laura Perry, PhD
• Email: Lperry5@tulane.edu
• Phone: 504-988-8906

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.